https://www.selleckchem.com/products/ars-853.html
1, p = 0.004) and OS (HR = 9.0, 95%CI = 1.9-43.5, p = 0.019). Tracking CAML sizes throughout CRT as a minimally invasive biomarker may serve as a prognostic tool in mapping EC progression, and further studies are warranted to determine if presence of these cells prior to treatment suggest diagnostic value for at-risk populations. Tracking CAML sizes throughout CRT as a minimally invasive biomarker may serve as a prognostic tool in mapping EC progression, and further studies are warranted to determine if presence of these cells prior to
Like
Comment
Share
